https://www.selleckchem.com/products/gsk503.html
001) and a decreased skin reactivity to apples. Oral allergy syndrome to other birch prFA than apple also decreased (p .05). Moreover, daily rhinoconjunctivitis CSMS declined by 34% (p .001), as did conjunctival reactivity to birch pollen extract by 27% (p .01), while specific IgG to Mal d 1 and Bet v 1 increased (p .01). After 8 months of therapy, patients showed increased tolerance to apples (p less then .001) and a decreased skin reactivity to apples. Oral allergy syndrome to other birch prFA than apple also decr
Like
Comment
Share
